NCT03013634

Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Tianjin First Central Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to evaluate the protective effect of dexmedetomidine on myocardial injury during liver transplantation

Detailed description

Liver transplantation surgery may lead to myocardial injury. Dexmedetomidine, a highly specific α2-adrenoeptor agonist, has sedative and analgesic properties without significant respiratory depression at the clinically approved dosage. Some investigations indicated that dexmedetomidine was able to protect the myocardium via improving the activity of Na+-K+-adenosine triphosphate enzyme and Ca2+-adenosine triphosphate, alleviating inflammation reaction and avoiding Ca2+ overload. However, the effect and the mechanism of dexmedetomidine on myocardial injury during liver transplantation remain unclear.

Conditions

• Evidence of Liver Transplantation
• Myocardial Injury

Interventions

Type	Name	Description
DRUG	Dexmedetomidine	Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
DRUG	Normal saline	Equal volume normal saline substitute for dexmedetomidine

Timeline

• Start date: 2016-10-01
• Primary completion: 2017-10-01
• Completion: 2017-11-01
• First posted: 2017-01-06
• Last updated: 2017-01-06

Locations

1 site across 1 country: China